Crisugabalin
{{Short description|Drug for chronic pain}}
{{Infobox drug
| drug_name =
| INN =
| type =
| image = Crisugabalin.svg
| image_class = skin-invert-image
| alt =
| caption =
| pronounce =
| tradename =
| Drugs.com =
| MedlinePlus =
| pregnancy_AU =
| pregnancy_AU_comment =
| pregnancy_category=
| routes_of_administration =
| ATCvet =
| ATC_prefix =
| ATC_suffix =
| legal_AU =
| legal_AU_comment =
| legal_BR =
| legal_BR_comment =
| legal_CA =
| legal_CA_comment =
| legal_DE =
| legal_DE_comment =
| legal_NZ =
| legal_NZ_comment =
| legal_UK =
| legal_UK_comment =
| legal_US =
| legal_US_comment =
| legal_EU =
| legal_EU_comment =
| legal_UN =
| legal_UN_comment =
| legal_status = Investigational
| bioavailability =
| protein_bound =
| metabolism =
| metabolites =
| onset =
| elimination_half-life =
| duration_of_action=
| excretion =
| CAS_number_Ref = {{cascite|correct|CAS}}
| CAS_number = 2209104-84-5
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = Q3MK7E8686
| PubChem =
| DrugBank =
| IUPAC_name =
| C = 12 | H = 19 | N = 1 | O = 2
}}
Crisugabalin (HSK16149) is a selective GABA analog in development for the treatment of chronic pain. It has a wider therapeutic index than pregabalin, which has a similar mechanism of action. In China, it was approved in May 2024 for the treatment of diabetic peripheral neuropathic pain{{cite web | url = https://baipharm.chemlinked.com/news/monthly-report-new-drug-approvals-in-china-may-2024 | title = Monthly Report: New Drug Approval in China, May 2024 }} and approved in July 2024 for the treatment of postherpetic neuralgia.{{Cite web|title=海思科苯磺酸克利加巴林胶囊获批新适应症|url=https://www.phirda.com/artilce_35771.html|work=PhIRDA|date=19 July 2024|access-date=26 April 2025}} In the United States, it is in Phase III trials as of 2023.{{cite journal |last1=Gou |first1=Xiaoli |last2=Yu |first2=Xiaojuan |last3=Bai |first3=Dongdong |last4=Tan |first4=Bowei |last5=Cao |first5=Pingfeng |last6=Qian |first6=Meilin |last7=Zheng |first7=Xiaoxiao |last8=Chen |first8=Lei |last9=Shi |first9=Zongjun |last10=Li |first10=Yao |last11=Ye |first11=Fei |last12=Liang |first12=Yong |last13=Ni |first13=Jia |title=Pharmacology and Mechanism of Action of HSK16149, a Selective Ligand of α2δ Subunit of Voltage-Gated Calcium Channel with Analgesic Activity in Animal Models of Chronic Pain |journal=The Journal of Pharmacology and Experimental Therapeutics |date=March 2021 |volume=376 |issue=3 |pages=330–337 |doi=10.1124/jpet.120.000315 |issn=1521-0103|doi-access=free |pmid=33293377 }}{{cite journal | doi = 10.2337/db23-224-OR | title = 224-OR: The Efficacy and Safety of HSK 16149 in Chinese with Diabetic Peripheral Neuropathic Pain—A Randomized, Double-Blinded, Placebo and Pregabalin-Controlled Phase II/III Study | date = 2023 | last1 = Guo | first1 = Xiaohui | last2 = Zhang | first2 = Tingting | last3 = Yuan | first3 = Geheng | last4 = Yukun | first4 = LI | last5 = Hua Ma | first5 = Jian | last6 = Hong-Mei | first6 = LI | journal = Diabetes | volume = 72 }} The drug can be administered with or without food.{{cite journal |last1=Wu |first1=Qingqing |last2=Zhu |first2=Huijuan |last3=Song |first3=Rong |last4=Zhang |first4=Mengqi |last5=Li |first5=Fangqiong |last6=Zeng |first6=Weifang |last7=Wang |first7=Wei |last8=Jia |first8=Jingying |last9=Yu |first9=Chen |last10=Liu |first10=Yanmei |title=Effect of a high-fat and high-calorie food on the pharmacokinetics of a novel, potent GABA analog HSK16149 in healthy subjects |journal=Pharmacology Research & Perspectives |date=June 2023 |volume=11 |issue=3 |pages=e01102 |doi=10.1002/prp2.1102|doi-access=free |pmid=37208866 |pmc=10199234 }}